Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial

ConclusionsBased on high persistence and patient satisfaction rates, the 100-mg dose appears optimal for most patients. For those who adjusted dose levels, dose adjustments appeared beneficial to improve efficacy or tolerability, retaining patients on treatment. Collectively, the data suggest that patients who experienced efficacy continued to use lasmiditan regardless of the occurrence or frequency of AEs, and continued use appeared associated with fewer AEs.Trial registrationEuropean Union Drug Regulating Authorities Clinical Trials Database (EudraCT): 2018 –001661-17; ClinicalTrials.gov: NCT03670810; registration date: September 12, 2018.Graphical Abstract
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research